• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
  • Guest Content
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Opinion
    • Elevenses
  • Business
  • Food
  • Travel
  • Property
  • JOBS
  • All
    • All Entertainment
    • Film
    • Sport
    • Tech/Auto
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Opinion
    • Elevenses
  • Business
  • Food
  • Travel
  • Property
  • JOBS
  • All
    • All Entertainment
    • Film
    • Sport
    • Tech/Auto
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
No Result
View All Result
The London Economic
No Result
View All Result
Home News

Psychedelic drug improves symptoms of depression for six months – study

Dimethyltryptamine is a powerful hallucinogenic found in several plants and is the psychoactive compound found in ayahuasca.

Joseph Connor by Joseph Connor
2023-04-04 17:43
in News, Politics
FacebookTwitterLinkedinEmailWhatsapp

A psychedelic drug that gives trips lasting half an hour improves the symptoms of moderate to severe depression for up to six months, early trial results suggest.

Biotechnology company Small Pharma announced the results of its phase 2a clinical trials of the effects of a pharmaceutical-grade formulation of Dimethyltryptamine (SPL026) on major depressive disorder, simply referred to as depression.

The drug is a powerful hallucinogenic found in several plants and is the psychoactive compound found in ayahuasca, a compound used in shamanic rituals in South America.

In the study, 34 patients were given the drug during a clinical session with supportive therapy.

The individual sessions lasted less than two-and-a-half hours, and included a preparation session with a therapist, a psychedelic experience after administering the drug (where the therapist was present) lasting less than 30 minutes, and a therapy session to help patients process their trip.

According to data from the trial, among the patients who had achieved remission within three months of taking the drug, 64% sustained remission to six months.

Robin Carhart-Harris, director of the psychedelics division at the Weill Institute for Neurosciences at the University of California San Francisco, and Ralph Metzner, distinguished professor of neurology, psychiatry and behavioural sciences, said: “These data indicate that SPL026 can elicit a fast-acting antidepressant response that appears to be enduring in several cases.

“Recent neuroimaging and preclinical findings imply a regenerative action with DMT and other related serotonergic agonists.”

The trial investigated the effectiveness and safety of 21.5mg of SPL026 given intravenously with supportive therapy in 34 patients with moderate or severe depression.

RelatedPosts

Driver mounts pavement and drives through pedestrians to avoid Just Stop Oil protest

Suella Braverman made front-page news 23 years ago – accused of ‘corruption’

Teenager Mizzy arrested over TikTok ‘prank’

Emily Maitlis nails Guto Harri on Boris Johnson’s culture of lying

Today we are pleased to share positive six-month data from our lead candidate in patients with Major Depressive Disorder (MDD). Approximately two-thirds of trial patients achieving remission sustained remission to six-months.

Link to the full release: https://t.co/qrq6rgyFjd pic.twitter.com/5WxNgM4CEl

— Small Pharma (@SmallPharma) April 4, 2023

“This new data shows that the antidepressant effect was sustained for six months in two-thirds of patients who were in remission at an earlier time-point in the study.

“As we finalise the design of the Phase IIb study, this data helps to inform our understanding of treatment durability and our approach to patient retreatment within the trial.”

George Tziras, chief executive of Small Pharma, said: “We are pleased to see that participants in our study experienced durable relief from their depression for an extended period of time.

“Given these clinical outcomes from one or two treatments, this could further offer potential value to healthcare systems that face challenges with patients who struggle to adhere to their daily antidepressant use.”

Dr James Rucker, consultant psychiatrist and senior clinical lecturer at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, said: “Phase 2a trials generally cannot tell us whether a treatment is effective, but they can pave the way for further trials that may. This is the case here.

“On the face of it, this data is encouraging. However, this part of the study does not include a comparator group so it is not possible to gauge whether participants may have improved for reasons unrelated to the drug and therapy provided.

“It is important to note that, when all participants who took part in this part of the trial were considered, the majority were not  in remission.

“This is not unusual in trials in major depression, and underpins the observation that major depression is a multifactorial problem that responds to psychological and social treatments, as well as biological.

“This work is a good foundation for further, more rigorous trials using DMT given alongside psychotherapy for people suffering with major depression.”

You may also like: Tories recycle wet wipe announcement for the THIRD time in five years

Content Protection by DMCA.com
Tags: Dimethyltryptamine

Since you are here

Since you are here, we wanted to ask for your help.

Journalism in Britain is under threat. The government is becoming increasingly authoritarian and our media is run by a handful of billionaires, most of whom reside overseas and all of them have strong political allegiances and financial motivations.

Our mission is to hold the powerful to account. It is vital that free media is allowed to exist to expose hypocrisy, corruption, wrongdoing and abuse of power. But we can't do it without you.

If you can afford to contribute a small donation to the site it will help us to continue our work in the best interests of the public. We only ask you to donate what you can afford, with an option to cancel your subscription at any point.

To donate or subscribe to The London Economic, click here.

The TLE shop is also now open, with all profits going to supporting our work.

The shop can be found here.

You can also SUBSCRIBE TO OUR NEWSLETTER .

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending

Elevenses: The Thing About Wrexham’s Cinderella Story

Elevenses: Exposing the Tories’ Deepfake Illegal Immigration Bill

Elevenses: Rishi’s Finest Hour

More from TLE

Rookie PCSOs hailed as heroes after running into burning house to save toddler & mum

Another one! Ex-head of Covid taskforce had No 10 leaving party

QuotedData’s economic round up – August 2017

Tory MP praises Patel for refusing to offer asylum to Ukrainians – saying we have ‘done our bit’

UK will strike trade deals with countries violating human rights, Dominic Raab says

Brexiter Tory MP’s story of public support for PM didn’t seem to fool anyone

LIVE: Cave In

Elevenses: Brexit betrayal theory

Starmer’s quick-fire response to Corbyn question will raise a few eyebrows

Exploring a New Forest escape at a Mediterranean pace

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: [email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.